Zoetis (ZTS) Rating Reiterated by Piper Jaffray Companies

Zoetis (NYSE:ZTS)‘s stock had its “buy” rating reiterated by analysts at Piper Jaffray Companies in a research note issued on Thursday. They currently have a $86.00 price target on the stock. Piper Jaffray Companies’ price objective points to a potential upside of 12.24% from the company’s current price.

Other analysts also recently issued reports about the company. Cantor Fitzgerald restated a “buy” rating and issued a $75.00 price objective on shares of Zoetis in a research report on Tuesday, September 26th. BidaskClub downgraded Zoetis from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, September 20th. Zacks Investment Research upgraded Zoetis from a “hold” rating to a “buy” rating and set a $71.00 price objective on the stock in a research report on Thursday, October 12th. Stifel Nicolaus restated a “buy” rating and issued a $65.00 price objective on shares of Zoetis in a research report on Tuesday, October 24th. Finally, Jefferies Group restated a “buy” rating on shares of Zoetis in a research report on Friday, November 10th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and fourteen have given a buy rating to the company’s stock. Zoetis currently has a consensus rating of “Buy” and a consensus target price of $73.72.

Zoetis (NYSE ZTS) traded up $0.29 on Thursday, reaching $76.62. The company’s stock had a trading volume of 3,476,402 shares, compared to its average volume of 1,950,000. The company has a debt-to-equity ratio of 2.45, a quick ratio of 1.95 and a current ratio of 2.80. The stock has a market capitalization of $37,340.00, a P/E ratio of 40.33, a price-to-earnings-growth ratio of 1.83 and a beta of 1.06. Zoetis has a one year low of $52.00 and a one year high of $77.03.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, November 2nd. The company reported $0.65 EPS for the quarter, topping the Zacks’ consensus estimate of $0.63 by $0.02. The company had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.32 billion. Zoetis had a return on equity of 62.39% and a net margin of 18.29%. Zoetis’s quarterly revenue was up 8.5% compared to the same quarter last year. During the same period in the previous year, the business earned $0.52 earnings per share. equities analysts anticipate that Zoetis will post 2.36 EPS for the current fiscal year.

Institutional investors have recently added to or reduced their stakes in the stock. Northwestern Mutual Wealth Management Co. increased its stake in Zoetis by 16.8% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 1,598 shares of the company’s stock valued at $100,000 after purchasing an additional 230 shares during the last quarter. Steward Partners Investment Advisory LLC acquired a new position in Zoetis in the third quarter valued at $114,000. Harfst & Associates Inc. increased its stake in Zoetis by 16.1% in the second quarter. Harfst & Associates Inc. now owns 1,878 shares of the company’s stock valued at $117,000 after purchasing an additional 260 shares during the last quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. increased its stake in Zoetis by 251.9% in the third quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,900 shares of the company’s stock valued at $121,000 after purchasing an additional 1,360 shares during the last quarter. Finally, Shine Investment Advisory Services Inc. increased its stake in Zoetis by 86.5% in the third quarter. Shine Investment Advisory Services Inc. now owns 2,242 shares of the company’s stock valued at $143,000 after purchasing an additional 1,040 shares during the last quarter. Hedge funds and other institutional investors own 93.14% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This story was first reported by Week Herald and is the property of of Week Herald. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this story can be viewed at https://weekherald.com/2018/01/20/zoetis-zts-rating-reiterated-by-piper-jaffray-companies.html.

About Zoetis

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Analyst Recommendations for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply